Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites

Clinical Nephrology

Volumn 61, Issue 3, 2004, Pages 191-197

  Klemm, A ^a   Franke, C ^a   Busch, M ^a   Muller A ^a   Franke, S ^a   Lang, D ^b   Passlick Deetjen, J ^b   Stein, G ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

Advanced glycation end products; Carboxymethyllysine; Cystathionine; Dimethylglycine; Hemodialysis; High flux polysulfone; Homocysteine; Pentosidine

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; CYSTATHIONINE; DIMETHYLGLYCINE; HOMOCYSTEINE; PENTOSIDINE; POLYSULFONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSIS MEMBRANE; FEMALE; FLUORESCENCE; HEMODIALYSIS; HUMAN; MALE; MEMBRANE PERMEABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 1642373099     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP61191     Document Type: Article

References (30)

1. 2-microglobulin concentration after cuprophane haemodialysis (letter). Lancet 1: 628-629
2. Bucala R, Vlassara H 1995 Advanced glycosylation endproducts in diabetic renal disease: Clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif 13: 160-170
3. Colaco CA, Ledesma MD, Harrington CR, Avila J 1996 The role of the Maillard reaction in other pathologies: Alzheimer's disease. Nephrol Dial Transplant 11 (Suppl 5): 7-12
4. Friedman AN, Bostom A G, Selhub J, Levey AS, Rosenberg IH 2001 The kidney and homocysteine metabolism. J Am Soc Nephrol 12: 2181-2189
5. Gerdemann A, Lemke HD, Nothdurft A, Heidland A, Munch G, Bahner U, Schinzel R 2000 Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 54: 276-283
6. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R 2002 Plasma levels of advanced glycation end products during haemodialysis, hemodiafiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Transplant 17: 1045-1049
7. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E 1999 Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 14: 1968-1975
8. Henning BF, Riezler R, Tepel M, Langer K, Raidt H, Graefe U, Zidek W 1999 Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 83: 314-322
9. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC 2000 Randomized trial of high-flux vs low-flux hemodialysis: Effects on homocysteinc and lipids. Nephrol Dial Transplant 15: 1029-1034
10. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, van Ypersele de Strihou C, Miyata T 1999 Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "cArbonyl stress". Kidney Int 55: 2487-2492
11. Kitiyakara C, Gonin J, Massy Z, Wilcox CS 2000 Non-traditional cardiovascular disease risk factors in end-stage renal disease: Oxidative stress and hyperhomocysteinemia. Curr Opin Nephrol Hypertens 9: 477-487
12. McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST 2001 Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int 59: 2267-2272
13. Miyata T, Kurokawa K 1999 Carbonyl stress: Increased carbonyl modification of proteins by autoxidation products of carbohydrates and lipids in uremia. Int J Artif Organs 22: 195-198
14. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K 1996 Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7: 1198-1206
15. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C 1997 Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 51: 880-887
16. Raj DS, Choudhury D, Welbourne TC, Levi M 2000 Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 35: 365-380
17. Ronco C, Bowry S 2001 Nanoscale modulation of the pore dimensions, size distribution and structure of a new polysulfone-based high-flux dialysis membrane. Int J Artif Organs 24: 726-735
18. Ronco C, Bowry SK, Brendolan A, Crepaldi C, Soffiati G, Fortunato A, Bordoni V, Granziero A, Torsello G, La Greca G 2002 Hemodialyzer: From macrodesign to membrane nanostructure, the case of the FX class of hemodialyzers. Kidney Int 61 (Suppl 80): 126-142
19. Schinzel R, Munch G, Heidland A, Sebekova K 2001 Advanced glycation end products in end-stage renal disease and their removal. Nephron 87: 295-303
20. Stabler SP, Lindenbaum J, Savage DG, Allen RH 1993 Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81: 3404-3413
21. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J 2001a Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 16: 999-1008
22. Stein G, Franke S, Sperschneider H, Vienken J, Ueda Y, Miyata T, Kurokawa K 1999 Decrease in serum pentosidine levels of ESRD patients during polysulfone haemodialysis (letter). Nephrol Dial Transplant 14: 1606-1608
23. Stein G, Muller A, Busch M, Fleck C, Sperschneider H 2001b Homocysteine, its metabolites and B group vitamins in renal transplant patients. Kidney Int Suppl 78: S262-S265
24. Sunder-Plassmann G, Horl WH 2001 Pathophysiology and treatment of hyperhomocysteinemia in ESRD patients. Hemodial Int 5: 86-91
25. Thornalley PJ 1998 Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy le grand) 44: 1013-1023
26. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH 1993 Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 39: 1764-1779
27. van Guldener C, Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, Donker AJ, Stehouwer CD, De Meer K 1999 Homocysteine and methionine metabolism in ESRD: A stable isotope study. Kidney Int 56: 1064-1071
28. van Tellingen A, Grooteman MP, Bartels PC, Van Limbeek J, van Guldener C, Wee PM, Nube MJ 2001 Long-term reduction of plasma homocysteine levels by superflux dialyzers in hemodialysis patients. Kidney Int 59: 342-347
29. Vlassara H 1994 Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 12: 54-59
30. Vlassara H 1996 Advanced glycation end-products and atherosclerosis. Ann Med 28: 419-426